Integra LifeSciences Holdings Corporation Common Stock (IART)

FairStock Score: 34/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for durable businesses at sensible prices. Integra makes specialized surgical products in neurosurgery and wound care. But the reported record is uneven. In fiscal 2023, the year ended 2023-12-31, the company earned $67.7M. In fiscal 2024, the year ended 2024-12-31, it lost $6.9M. In fiscal 2025, the year ended 2025-12-31, it lost $516.5M, or $6.74 per diluted share. That makes it a turnaround by the given Lynch category: a loss in the latest year after earlier profits. The latest filing, in fiscal Q2 2026, the quarter ended 2026-06-30, showed $418.8M revenue and $4.5M net income, or $0.06 diluted EPS, a slim 1.07% margin. In fiscal Q1 2026, the quarter ended 2026-03-31, it lost $4.6M. So profitability is not yet consistent. Revenue growth is only 0.76% per FairStock. Free cash flow is $11.6M trailing twelve months, a 1.1% FCF yield. Debt to equity is 1.96, and the Altman Z-Score of 0.85 signals balance-sheet risk. The Piotroski F-Score of 7/9 is encouraging, and profit growth of 100.93% is a FairStock figure off a collapsed base. At the October 13, 2026 close of $13.85, P/B is 1.03, EV/EBITDA is 11.87, ROE is -0.70%, and ROCE is 2.83%. A negative P/E of -153.89 means earnings are not useful. The price could work if margins recover, but Graham would want a margin of safety and Buffett would want consistent returns on capital. I see a speculative turnaround, not a clear bargain.

In plain English: Integra LifeSciences makes surgical tools and medical products used in brain, nerve, ear, nose, throat, and wound care. The business looks weak right now: it reported a small profit in the latest quarter but a large loss for fiscal 2025, and it carries a lot of debt. At $13.85, the stock trades near the value of its net assets, but the numbers do not show a clearly cheap or strong company.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer